Total Valuation
Thiogenesis Therapeutics Corp has a market cap or net worth of C$43.39M. The enterprise value is C$25.10M.
Market CapC$43.39M
Enterprise ValueC$25.10M
Share Statistics
Thiogenesis Therapeutics Corp has 69,979,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding69,979,650
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Thiogenesis Therapeutics Corp’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Thiogenesis Therapeutics Corp is ―. Thiogenesis Therapeutics Corp’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Thiogenesis Therapeutics Corp had revenue of ― and earned -5.06M in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income-5.21M
Pretax Income―
Net Income-5.06M
EBITDA-5.06M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Thiogenesis Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change-3.13%
50-Day Moving Average0.52
200-Day Moving Average0.55
Relative Strength Index (RSI)65.19
Average Volume (3m)43.77K
Important Dates
Thiogenesis Therapeutics Corp upcoming earnings date is Nov 24, 2026, During Market Hours (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 24, 2026
Ex-Dividend Date―
Financial Position
Thiogenesis Therapeutics Corp as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Thiogenesis Therapeutics Corp has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Thiogenesis Therapeutics Corp EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Thiogenesis Therapeutics Corp has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Thiogenesis Therapeutics Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-11.28%